Celyne Bueno Hume, MD
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor (Joint appointment), Department of General Internal Medicine, Division of Cancer Medicine, The University of Texas Medical Branch, Galveston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2003 | University of TX Medical Branch, Galveston, Texas, US, MD |
| 1999 | Rice University, Houston, Texas, US, Bachelor of Arts, BA |
| 1998 | Duke University, Rome, IT, Classical Studies, Intercollegiate |
Postgraduate Training
| 2007-2010 | Clinical Fellowship, Medical Oncology/Hematology, Mayo Clinic, Jacksonville, Florida |
| 2003-2007 | Clinical Internship, Internal Medicine, Louisiana State University, Baton Rouge, Louisiana |
Board Certifications
| 2010 | Medical Oncology - American Board of Internal Medicine |
| 2010 | Hematology - American Board of Internal Medicine |
| 2006 | Internal Medicine - American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2018
Other Appointments/Responsibilities
Physician, Dixon Correctional Institute: Louisiana Department of Corrections, Jackson, LA, 2005 - 2007
Institutional Committee Activities
Chair, Medical Practice Committee, 2022 - Present
Member, Thoracic Enterprise Wide Scheduling Task Force, 2020 - Present
Member, Professional Liability Committee, 2020 - Present
Vice Chair, Medical Practice, 2019 - 2022
Officer, MDA League City Safety, 2019 - Present
Speaker, Speakers Bureau, 2017 - Present
General Oncology Representative, Credentials Committee of the Medical Staff, 2017 - 2020
Physician Lead, Patient Safety Project on Oral Chemotherapy at Home Administration, 2016 - Present
Member, Bay Area Work Group, 2013 - Present
Member, Medical Practice, 2012 - Present
Member, HAL Clinical Research Committee, 2011 - Present
Member, CN Protocol Review, Integration and Strategic Management (PRISM), 2011 - Present
Honors & Awards
| 2024 | Consumer Assessment of Healthcare Providers and Systems (CAHPS), The University of Texas MD Anderson Cancer Center |
| 2003 | Phi Kappa Phi Honor Society |
| 2003 | AMWA's Jane M. Glasgow Achievement Citation |
| 2002 | Alpha Omega Alpha Honor Society |
| 2002 | TMA Physician Oncology Education Scholarship |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Wang, K, Du, R, Roy Chowdhuri, S, Li, ZT, Hong, L, Vokes, N, Elamin, YY, Bueno Hume, C, Skoulidis, F, Gay, CM, Blumenschein, GR, Fossella, FV, Tsao, A, Zhang, J, Karachaliou, N, O'Brate, A, Gann, CN, Lewis, J, Rinsurongkawong, W, Lee, JJ, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Altan, M, Le, X. Brief Report. JTO Clinical and Research Reports 4(8), 2023. PMID: 37649681.
- Martel, J, Cho, WC, Runge, JS, Patel, A, Tayar, JH, Woodman, K, Bueno Hume, C, Curry, JL, Heberton, MM. Durvalumab-associated generalized morphea with overlapping vitiligo. JAAD Case Reports 30:83-86, 2022. PMID: 36407485.
Other Articles
- Leon-Ferre RA, Perez EA, Hillman DW, Bueno C, Perez AT, Chen B, Jenkins RB, Northfelt DW, Johnson DB, Carolla RL, Zon RT, Moreno-Aspitia A N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Breast Cancer Res Treat 182(None):613-622, 2020. PMID: None.
- Patel TA, Colon-Otero G, Bueno Hume C, Copland JA, Perez EA Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist 15(5):466-75, 2010. PMID: 20427382.
- Williams TP, Cox MW, Jana B, Ross MI, Fisher SB, Walker JP, Hume CB, Mayo LL, Tyler DS Vascular stenting of a malignant arterial blowout as a bridge to effective systemic and regional therapy. J Surg Oncol 129(7):1209-1212. PMID: 38534025.
- Patel T, Moreno-Aspitia A, Hume C, Saurel C, Roy V, Perez E A Retrospective Review of Patients with Adenoid Cystic Breast Cancer Treated at Mayo Clinic. Cancer Res 69(24 Suppl):2055. PMID: None.
Abstracts
- Hume C, Moreno-Aspitia A, Hillman D, Perez A, Chen B, Jenkins R, Dueck A, Johnson D, Carolla R, A Perez AE. Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E. None None(None):None. PMID: None.
Patient Reviews
CV information above last modified November 18, 2024